Nicole A. Swartwood

Nicole A. Swartwood

Auto-generated profile, based on publicly available information

Nicole A. Swartwood

Harvard University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2022 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
MCMelanie H. Chitwood
Melanie H. Chitwood
MRMarcus Russi
Marcus Russi
KGKenneth Gunasekera
Kenneth Gunasekera
JHJoshua Havumaki
Joshua Havumaki
FKFayette Klaassen
Fayette Klaassen
NMNicolas A Menzies
Nicolas A Menzies
Reported COVID-19 cases and deaths provide a delayed and incomplete picture of SARS-CoV-2 infections in the United States (US). Accurate estimates of both the timing and magnitude of infections are needed to characterize viral transmission dynamics and better understand COVID-19 disease burden. We estimated time trends in SARS-CoV-2 transmission and other COVID-19 outcomes for every county in the US, from the first reported COVID-19 case in January 13, 2020 through January 1, 2021. To do so we employed a Bayesian modeling approach that explicitly accounts for reporting delays and variation in case ascertainment, and generates daily estimates of incident SARS-CoV-2 infections on the basis of reported COVID-19 cases and deaths. The model is freely available as the covidestim R package. Nationally, we estimated there had been 49 million symptomatic COVID-19 cases and 404,214 COVID-19 deaths by the end of 2020, and that 28% of the US population had been infected. There was county-level variability in the timing and magnitude of incidence, with local epidemiological trends differing substantially from state or regional averages, leading to large differences in the estimated proportion of the population infected by the end of 2020. Our estimates of true COVID-19 related deaths are consistent with independent estimates of excess mortality, and our estimated trends in cumulative incidence of SARS-CoV-2 infection are consistent with trends in seroprevalence estimates from available antibody testing studies. Reconstructing the underlying incidence of SARS-CoV-2 infections across US counties allows for a more granular understanding of disease trends and the potential impact of epidemiological drivers.

23 November 2022 in medRxiv
Verified
Preprint
Open access
PDF file
FKFayette Klaassen
Fayette Klaassen
MCMelanie H. Chitwood
Melanie H. Chitwood
TCTed Cohen
Ted Cohen
VPVirginia E. Pitzer
Virginia E. Pitzer
MRMarcus Russi
Marcus Russi
NMNicolas A Menzies
Nicolas A Menzies
Importance: While a substantial fraction of the US population was infected with SARS-CoV-2 during December 2021 – February 2022, the subsequent evolution of population immunity against SARS-CoV-2 Omicron variants reflects the competing influences of waning protection over time and acquisition or restoration of immunity through additional infections and vaccinations. Objective: To estimate changes in population immunity against infection and severe disease due to circulating SARS-CoV-2 Omicron variants in the United States from December 2021 to November 2022, and to quantify the protection against a potential 2022-2023 winter SARS-CoV-2 wave. Design, setting, participants: Bayesian evidence synthesis of reported COVID-19 data (diagnoses, hospitalizations), vaccinations, and waning patterns for vaccine- and infection-acquired immunity, using a mathematical model of COVID-19 natural history. Main Outcomes and Measures: Population immunity against infection and severe disease from SARS-CoV-2 Omicron variants in the United States, by location (national, state, county) and week. Results: By November 9, 2022, 94% (95% CrI, 79%–99%) of the US population were estimated to have been infected by SARS-CoV-2 at least once. Combined with vaccination, 97% (95%–99%) were estimated to have some prior immunological exposure to SARS-CoV-2. Between December 1, 2021 and November 9, 2022, protection against a new Omicron infection rose from 22% (21%–23%) to 63% (51%–75%) nationally, and protection against an Omicron infection leading to severe disease increased from 61% (59%–64%) to 89% (83%–92%). Increasing first booster uptake to 55% in all states (current US coverage: 34%) and second booster uptake to 22% (current US coverage: 11%) would increase protection against infection by 4.5 percentage points (2.4–7.2) and protection against severe disease by 1.1 percentage points (1.0–1.5). Conclusions and Relevance: Effective protection against SARS-CoV-2 infection and severe disease in November 2022 was substantially higher than in December 2021. Despite this high level of protection, a more transmissible or immune evading (sub)variant, changes in behavior, or ongoing waning of immunity could lead to a new SARS-CoV-2 wave. Key points: Question: How did population immunity against SARS-CoV-2 infection and subsequent severe disease change between December 2021, and November 2022? Findings: On November 9, 2022, the protection against a SARS-CoV-2 infection with the Omicron variant was estimated to be 63% (51%–75%) in the US, and the protection against severe disease was 89% (83%–92%). Meaning: As most of the newly acquired immunity has been accumulated in the December 2021-February 2022 Omicron wave, risk of reinfection and subsequent severe disease remains present at the beginning of the 2022-2023 winter, despite high levels of protection.

1 April 2024 in Annals of Internal Medicine
Verified
Journal Article
Closed access
YLYunfei Li
Yunfei Li
MRMathilda Regan
Mathilda Regan
NSNicole A. Swartwood
Nicole A. Swartwood
TBTerrika Barham
Terrika Barham
GAGarrett R. Beeler Asay
Garrett R. Beeler Asay
NMNicolas A Menzies
Nicolas A Menzies
Elevated tuberculosis (TB) incidence rates have recently been reported for racial/ethnic minority populations in the United States. Tracking such disparities is important for assessing progress toward national health equity goals and implementing change. To quantify trends in racial/ethnic disparities in TB incidence among U.S.-born persons. Time-series analysis of national TB registry data for 2011 to 2021. United States. U.S.-born persons stratified by race/ethnicity. TB incidence rates, incidence rate differences, and incidence rate ratios compared with non-Hispanic White persons; excess TB cases (calculated from incidence rate differences); and the index of disparity. Analyses were stratified by sex and by attribution of TB disease to recent transmission and were adjusted for age, year, and state of residence. In analyses of TB incidence rates for each racial/ethnic population compared with non-Hispanic White persons, incidence rate ratios were as high as 14.2 (95% CI, 13.0 to 15.5) among American Indian or Alaska Native (AI/AN) females. Relative disparities were greater for females, younger persons, and TB attributed to recent transmission. Absolute disparities were greater for males. Excess TB cases in 2011 to 2021 represented 69% (CI, 66% to 71%) and 62% (CI, 60% to 64%) of total cases for females and males, respectively. No evidence was found to indicate that incidence rate ratios decreased over time, and most relative disparity measures showed small, statistically nonsignificant increases. Analyses assumed complete TB case diagnosis and self-report of race/ethnicity and were not adjusted for medical comorbidities or social determinants of health. There are persistent disparities in TB incidence by race/ethnicity. Relative disparities were greater for AI/AN persons, females, and younger persons, and absolute disparities were greater for males. Eliminating these disparities could reduce overall TB incidence by more than 60% among the U.S.-born population. Centers for Disease Control and Prevention.

24 December 2021 in medRxiv
Verified
Preprint
Open access
PDF file
FKFayette Klaassen
Fayette Klaassen
MCMelanie H. Chitwood
Melanie H. Chitwood
TCTed Cohen
Ted Cohen
VPVirginia E. Pitzer
Virginia E. Pitzer
MRMarcus Russi
Marcus Russi
NMNicolas A Menzies
Nicolas A Menzies
Prior infection and vaccination both contribute to population-level SARS-CoV-2 immunity. We used a Bayesian model to synthesize evidence and estimate population immunity to prevalent SARS-CoV-2 variants in the United States over the course of the epidemic until December 1, 2021, and how this changed with the introduction of the Omicron variant. We used daily SARS-CoV-2 infection estimates and vaccination coverage data for each US state and county. We estimated relative rates of vaccination conditional on previous infection status using the Census Bureau’s Household Pulse Survey. We used published evidence on natural and vaccine-induced immunity, including waning and immune escape. The estimated percentage of the US population with a history of SARS-CoV-2 infection or vaccination as of December 1, 2021, was 88.2% (95%CrI: 83.6%-93.5%), compared to 24.9% (95%CrI: 18.5%-34.1%) on January 1, 2021. State-level estimates for December 1, 2021, ranged between 76.9% (95%CrI: 67.6%-87.6%, West Virginia) and 94.4% (95%CrI: 91.2%-97.3%, New Mexico). Accounting for waning and immune escape, the effective protection against the Omicron variant on December 1, 2021, was 21.8% (95%CrI: 20.7%-23.4%) nationally and ranged between 14.4% (95%CrI: 13.2%-15.8%, West Virginia), to 26.4% (95%CrI: 25.3%-27.8%, Colorado). Effective protection against severe disease from Omicron was 61.2% (95%CrI: 59.1%-64.0%) nationally and ranged between 53.0% (95%CrI: 47.3%-60.0%, Vermont) and 65.8% (95%CrI: 64.9%-66.7%, Colorado). While over three-quarters of the US population had prior immunological exposure to SARS-CoV-2 via vaccination or infection on December 1, 2021, only a fifth of the population was estimated to have effective protection to infection with the immune-evading Omicron variant. Significance: Both SARS-CoV-2 infection and COVID-19 vaccination contribute to population-level immunity against SARS-CoV-2. This study estimates the immunity and effective protection against future SARS-CoV-2 infection in each US state and county over 2020-2021. The estimated percentage of the US population with a history of SARS-CoV-2 infection or vaccination as of December 1, 2021, was 88.2% (95%CrI: 83.6%-93.5%). Accounting for waning and immune escape, protection against the Omicron variant was 21.8% (95%CrI: 20.7%-23.4%). Protection against infection with the Omicron variant ranged between 14.4% (95%CrI: 13.2%-15.8%%, West Virginia) and 26.4% (95%CrI: 25.3%-27.8%, Colorado) across US states. The introduction of the immune-evading Omicron variant resulted in an effective absolute increase of approximately 30 percentage points in the fraction of the population susceptible to infection.

2 January 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MCMarc N Conte
Marc N Conte
MGMatthew Gordon
Matthew Gordon
NSNicole A Swartwood
Nicole A Swartwood
RWRachel Wilwerding
Rachel Wilwerding
CYChu A Alex Yu
Chu A Alex Yu
Several observational studies from locations around the globe have documented a positive correlation between air pollution and the severity of COVID-19 disease. Observational studies cannot identify the causal link between air quality and the severity of COVID-19 outcomes, and these studies face three key identification challenges: 1) air pollution is not randomly distributed across geographies; 2) air-quality monitoring networks are sparse spatially; and 3) defensive behaviors to mediate exposure to air pollution and COVID-19 are not equally available to all, leading to large measurement error bias when using rate-based COVID-19 outcome measures (e.g., incidence rate or mortality rate). Using a quasi-experimental design, we explore whether traffic-related air pollutants cause people with COVID-19 to suffer more extreme health outcomes in New York City (NYC). When we address the previously overlooked challenges to identification, we do not detect causal impacts of increased chronic concentrations of traffic-related air pollutants on COVID-19 death or hospitalization counts in NYC census tracts.

3 September 2024 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
NSNicole A. Swartwood
Nicole A. Swartwood
YLYunfei Li
Yunfei Li
MRMathilda Regan
Mathilda Regan
SMSuzanne M. Marks
Suzanne M. Marks
TBTerrika Barham
Terrika Barham
NMNicolas A. Menzies
Nicolas A. Menzies
Significant progress has been made toward tuberculosis (TB) elimination in the US, resulting in one of the lowest TB incidence rates in the world.1 From 2010 to 2019, US TB incidence fell 25% to a rate of 2.7 cases per 100 000 persons, with a larger 44% decline among US-born persons, reaching a rate of 0.9 per 100 000 persons.2 TB disease arises from the progression of previously acquired Mycobacterium tuberculosis (Mtb) infection or a recent transmission event, with an estimated 13% of TB among US-born persons attributable to recent transmission from 2018 to 2019.2,3 TB case-fatality rates remained stable from 2010 to 2019.2 Despite these achievements in low TB incidence, transmission, and case-fatality rates, substantial racial and ethnic disparities persist in both TB incidence and case-fatality among US-born persons.3-5